Exploring liver fibrosis biomarkers in non-alcoholic fatty liver disease (NAFLD)

Exploring liver fibrosis biomarkers in non-alcoholic fatty liver disease (NAFLD) - Exploring liver fibrosis biomarkers in non-alcoholic fatty liver disease (NAFLD)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036576

Enrollment

200

Registered

2019-04-23

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD/NASH

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NAFLD/NASH was diagnosed by liver biopsy

Exclusion criteria

Exclusion criteria: Exclusion criteria included 1) daily alcohol consumption >30 g for males and >20 g for females; 2) other chronic liver diseases, such as viral hepatitis B or C, autoimmune hepatitis, Wilson disease, and hemochromatosis; 3) secondary causes of steatosis, such as drug-induced fatty liver disease, total parenteral nutrition, and inborn errors of metabolism.

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of liver fibrosis biomarkers in patients with nonalcoholic fatty liver disease	—

Secondary

Measure	Time frame
Effect of liver fibrosis on arteriosclerosis	—

Countries

Japan

Contacts

Public ContactTaeang Arai

Nippon medical school Chiba Hokusoh Hospital Division of Gastroenterology

taeangpark@yahoo.co.jp0476991111

Outcome results